Showing results (1-10 of 75) with videos related to
Sort By:
Pageof 8
Endocrine, Metabolic & Immune Disorders Drug Targets|March 17, 2015
S100A9 as a Pharmacological Target Molecule in Inflammation and CancerTomas Leanderson, David Liberg, Fredrik IvarsInternational Immunopharmacology|December 28, 2013
The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: leukocyte- and context-specific effectsAdnan Deronic, Sofia Helmersson, Tomas Leanderson, et al.International Immunopharmacology|March 11, 2011
Specific effect of immunomodulatory quinoline-3-carboxamide ABR-215757 in GM-CSF stimulated bone marrow cell cultures: block of initiation of proliferation of Gr-1+ cellsSofia Helmersson, Martin Stenström, Tomas Leanderson, et al.Biochemical and Biophysical Research Communications|April 22, 2018
Induction of S100A9 homodimer formation in vivoEva Källberg, Sahar Tahvili, Fredrik Ivars, et al.BMC Cancer|July 13, 2016
The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growthAdnan Deronic, Sahar Tahvili, Tomas Leanderson, et al.The Prostate|August 6, 2010
Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer modelEva Källberg, Pernilla Wikström, Anders Bergh, et al.Plos One|April 30, 2013
Human S100A9 protein is stabilized by inflammatory stimuli via the formation of proteolytically-resistant homodimersMatteo Riva, Zhifei He, Eva Källberg, et al.Plos One|May 10, 2018
Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouseSahar Tahvili, Marie Törngren, Dan Holmberg, et al.International Immunopharmacology|April 29, 2010
Selective depletion of splenic CD4 dendritic cells in mice treated with immunomodulatory quinoline-3-carboxamide ABR-215757Martin Stenström, Per Anderson, Lena Eroukhmanoff, et al.Pageof 8